Liberty Capital Management Inc. Purchases 1,128 Shares of Danaher Corporation $DHR

Liberty Capital Management Inc. lifted its position in shares of Danaher Corporation (NYSE:DHR) by 3.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,300 shares of the conglomerate’s stock after acquiring an additional 1,128 shares during the quarter. Danaher makes up about 1.4% of Liberty Capital Management Inc.’s investment portfolio, making the stock its 21st largest position. Liberty Capital Management Inc.’s holdings in Danaher were worth $6,973,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Hills Bank & Trust Co lifted its position in shares of Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock valued at $3,693,000 after buying an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC increased its stake in shares of Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after purchasing an additional 53 shares during the period. Sageworth Trust Co increased its stake in shares of Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock worth $493,000 after purchasing an additional 54 shares during the period. 1834 Investment Advisors Co. increased its stake in shares of Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 54 shares during the period. Finally, Bruce G. Allen Investments LLC increased its stake in shares of Danaher by 13.1% during the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 6.4%

Shares of DHR stock opened at $198.05 on Wednesday. The stock’s fifty day moving average price is $199.55 and its two-hundred day moving average price is $197.31. The company has a market cap of $141.82 billion, a PE ratio of 42.14, a P/E/G ratio of 2.65 and a beta of 0.75. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 27.23%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 11.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DHR. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research note on Friday, July 18th. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. UBS Group lowered their target price on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Barclays restated an “overweight” rating and set a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Guggenheim restated a “buy” rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.